<DOC>
	<DOC>NCT01461941</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety profiles of E6005 ointment in patients with atopic dermatitis compared to vehicle. The pharmacokinetic profile after topical application of E6005 is also assessed.</brief_summary>
	<brief_title>A Phase 2 Study of E6005 in Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Inclusion Criteria Adults of both genders aged 20 to 64 years at the time when the written informed consent is obtained. Outpatients diagnosed with atopic dermatitis. Exclusion Criteria Patients with a present illness of Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo contagious, psoriasis, connective tissue disorder, collagen disorder or Netherton's syndrome, etc., which could have an effect on the pathological evaluation of the atopic dermatitis. Patients with active infection that requires oral or intravenous administration of antibiotics, antifungal or antivirus agent/s at baseline. Patients with advanced disease or abnormal laboratory tests that would possibly affect the safety of the subject or the implementation of this study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>Atopic</keyword>
</DOC>